Deletion of the inducible nitric oxide synthase gene reduces peripheral morphine tolerance in a mouse model of chronic inflammation

Fundam Clin Pharmacol. 2010 Jun;24(3):317-23. doi: 10.1111/j.1472-8206.2009.00775.x. Epub 2009 Sep 14.

Abstract

The implication of inducible nitric-oxide synthase (iNOS) on peripheral tolerance to morphine was evaluated in wild-type (WT) and iNOS knockout mice. Chronic inflammation was induced by subplantar (s.p.) injection of Complete Freund's Adjuvant (CFA), and morphine tolerance by subcutaneous implantation of a 75 mg morphine-pellet. Withdrawal was assessed after the intraperitoneal injection of 2 mg/kg naloxone. Antinociception was assessed (Randall-Selitto test) 5 min after a fixed dose of s.p. morphine (16 microg). In the absence of inflammation, s.p. morphine did not induce antinociception, while during CFA-inflammation produced 47.4 +/- 0.8 and 38.8 +/- 2.7% inhibitions respectively, in each genotype (P < 0.05). In morphine-tolerant mice with CFA-inflammation, no antinociception could be elicited in WT mice (2.4 +/- 0.3% inhibition); however, iNOS knockout mice showed significant antinociception (33.1 +/- 0.9%) (P < 0.001). Thus, iNOS gene deletion partially prevented tolerance to the peripheral effects of morphine, and significantly attenuated withdrawal-induced hyperactivity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental / enzymology*
  • Arthritis, Experimental / genetics
  • Arthritis, Experimental / pathology
  • Chronic Disease
  • Disease Models, Animal*
  • Drug Tolerance / physiology*
  • Gene Deletion*
  • Inflammation / chemically induced
  • Inflammation / enzymology
  • Inflammation / genetics
  • Inflammation Mediators / administration & dosage
  • Inflammation Mediators / adverse effects
  • Inflammation Mediators / physiology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Morphine / administration & dosage*
  • Morphine / adverse effects
  • Naloxone / administration & dosage
  • Nitric Oxide Synthase Type II / deficiency*
  • Nitric Oxide Synthase Type II / genetics*
  • Nitric Oxide Synthase Type II / physiology
  • Pain Measurement / drug effects
  • Pain Measurement / methods
  • Substance Withdrawal Syndrome / enzymology
  • Substance Withdrawal Syndrome / genetics
  • Substance Withdrawal Syndrome / pathology

Substances

  • Inflammation Mediators
  • Naloxone
  • Morphine
  • Nitric Oxide Synthase Type II